Blog
RSS FeedPosted by Michael Wonder on 13 Mar 2025
First daily pill for endometriosis approved for NHS use
13 March 2025 - Today we've recommended the first long-term daily pill to treat endometriosis that could transform how this painful ...
Posted by Michael Wonder on 12 Mar 2025
Atezolizumab for the first-line treatment of adults with advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable
12 March 2025 - NICE is unable to make a recommendation on the use of atezolizumab (Tecentriq) in the NHS for ...
Posted by Michael Wonder on 12 Mar 2025
Zolbetuximab in combination with chemotherapy for the first-line treatment of adults with claudin-18.2 positive, HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma (final guidance)
12 March 2025 - NICE has published final evidence-based recommendations on the use of zolbetuximab (Vyloy) in combination with chemotherapy ...
Posted by Michael Wonder on 26 Feb 2025
Exagamglogene autotemcel for the treatment of patients with severe sickle cell disease
26 February 2025 - NICE has published final evidence-based recommendations on the use of exagamglogene autotemcel (Casgevy) for the treatment ...
Posted by Michael Wonder on 26 Feb 2025
Osimertinib mesylate for the adjuvant treatment of patients with EGFR mutation positive non-small-cell lung cancer after complete tumour resection (final guidance)
26 February 2025 - NICE has published final evidence-based recommendations on the use of osimertinib mesylate (Tagrisso) for the adjuvant ...
Posted by Michael Wonder on 21 Feb 2025
Green light for groundbreaking personalised cancer therapy that reprogrammes immune system
20 February 2025 - Final guidance published today recommends lisocabtagene maraleucel (Breyanzi; Bristol Myers Squibb) as an option for treating ...
Posted by Michael Wonder on 19 Feb 2025
Selpercatinib for the treatment of patients with advanced RET fusion positive non-small-cell lung cancer
19 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...
Posted by Michael Wonder on 19 Feb 2025
Durvalumab in combination with etoposide phosphate and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small-cell lung cancer
19 February 2025 - NICE has published final evidence-based recommendations on the use of durvalumab (Imfinzi) in combination with etoposide ...
Posted by Michael Wonder on 13 Feb 2025
Olaparib for the treatment of patients with advanced, BRCA mutation positive, HER2 negative breast cancer after chemotherapy
12 February 2025 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) for the treatment of ...
Posted by Michael Wonder on 13 Feb 2025
Selpercatinib for the treatment of patients with advanced thyroid cancer with a RET alteration untreated with a targeted cancer medicine
12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...
Posted by Michael Wonder on 13 Feb 2025
Selpercatinib for the treatment of patients with advanced thyroid cancer with a RET alteration after treatment with a targeted cancer medicine (final guidance)
12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...
Posted by Michael Wonder on 12 Feb 2025
Ganaxolone for the treatment of patients 2 years of age and older with seizures caused by CDKL5 deficiency disorder
12 February 2025 - NICE has published final evidence-based recommendations on the use of ganaxolone (Ztalmy) for the treatment of ...
Posted by Michael Wonder on 05 Feb 2025
Pembrolizumab for adjuvant treatment of patients with resected non-small-cell lung cancer (final guidance)
5 February 2025 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) for the adjuvant treatment ...
Posted by Michael Wonder on 05 Feb 2025
Elacestrant dihydrochloride for the treatment of patients with advanced, oestrogen receptor positive, HER2 negative breast cancer with an ESR1 mutation after endocrine treatment (final guidance)
5 February 2025 - Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation ...
Posted by Michael Wonder on 23 Jan 2025
Vadadustat for the treatment of adults with symptomatic anaemia on dialysis for chronic kidney disease
23 January 2025 - NICE has published final evidence-based recommendations on the use of vadadustat (Vafseo) for the treatment of ...